• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Congress approves one-year renewal diabetes research funding

Congress approves one-year renewal diabetes research funding

April 2, 2014
CenterWatch Staff

The U.S. Senate has approved legislation for a one-year extension of the Special Diabetes Program (SDP)—an initiative that accounts for roughly one-third of all federally funded type 1 diabetes (T1D) research in the U.S. The decision comes on the heels of the March 27 approval of the legislation by the U.S. House of Representatives, and will extend SDP funding for the National Institutes of Health (NIH) at the current level of $150 million, as part of the “Protecting Access to Medicare Act of 2014.”

With a one-year renewal, SDP-funded researchers will be able to continue promising clinical trials that are leading to improved therapies and ultimately a cure for T1D. T1D is an autoimmune disease in which the immune system attacks and destroys insulin-producing beta cells in the pancreas, rendering millions of Americans dependent on insulin injections and 24/7 vigilance to survive. The SDP has led to groundbreaking discoveries and new treatments that are improving the lives of people with both T1D and type 2 diabetes, demonstrating a strong return on the federal investment.

"JDRF and its volunteers across the nation are working every day to create a world without type 1 diabetes," said Jeffrey Brewer, president and CEO of JDRF. "The renewal of the Special Diabetes Program continues critical funding momentum for groundbreaking diabetes research—an investment that will not only improve the lives and health of millions of Americans, but will save the U.S. healthcare system billions of dollars in the long run."

The next step will be for President Obama to sign the legislation.

This latest extension of the SDP, which will run through September 2015, has been a focus of advocacy efforts by JDRF, a charitable supporter of T1D research worldwide. Among other research advances, SDP funding has accelerated the development of artificial pancreas technologies, led to the discovery of a drug that can help reverse vision loss in people with diabetic eye disease and launched a trial to test a therapy with potential to prevent diabetic kidney failure.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing